Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 16, 2018 - Issue 12
Submit an article Journal homepage
300
Views
7
CrossRef citations to date
0
Altmetric
Drug Profile

Dolutegravir-rilpivirine: first 2-drug regimen for HIV-positive adults

Martina ProperziDepartment of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, ItalyView further author information
,
Paola MagroDepartment of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, ItalyView further author information
,
Francesco CastelliDepartment of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, ItalyCorrespondence[email protected]
View further author information
&
Eugenia Quiros-RoldanDepartment of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, ItalyView further author information
Pages 877-887 | Received 30 Jul 2018, Accepted 01 Nov 2018, Published online: 14 Nov 2018

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Elahe Taki, Faezeh Soleimani, Arezoo Asadi, Hossein Ghahramanpour, Ali Namvar & Mohsen Heidary. (2022) Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV. Expert Review of Anti-infective Therapy 20:8, pages 1135-1147.
Read now
Arturo Ciccullo, Gianmaria Baldin, Alberto Borghetti & Simona Di Giambenedetto. (2020) Dolutegravir plus lamivudine for the treatment of HIV-1 infection. Expert Review of Anti-infective Therapy 18:4, pages 279-292.
Read now

Articles from other publishers (5)

Giovanni Del Fabro, Palmiro Mileto, Francesco Castelli & Eugenia Quiros-Roldan. (2023) Two cases of drug induced hypersensitivity to dolutegravir-rilpivirine fixed-dose combination: A case report. International Journal of Risk & Safety in Medicine 34:2, pages 155-159.
Crossref
Cecilia Tortajada, Lidia Castellano, Amando Mengual & Juan Flores. (2021) No decrease in CD4/CD8 ratio after 36 months therapy in patients switched to dual regimens containing rilpivirine. Enfermedades infecciosas y microbiologia clinica (English ed.) 39:2, pages 106-107.
Crossref
Cecilia Tortajada, Lidia Castellano, Amando Mengual & Juan Flores. (2021) No decrease in CD4/CD8 ratio after 36 months therapy in patients switched to dual regimens containing rilpivirine. Enfermedades Infecciosas y Microbiología Clínica 39:2, pages 106-107.
Crossref
Murugesan Vanangamudi, Sonali Kurup & Vigneshwaran Namasivayam. (2020) Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens. Current Opinion in Pharmacology 54, pages 179-187.
Crossref
Aleksandr Ianevski, Anil K Giri & Tero Aittokallio. (2020) SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Research 48:W1, pages W488-W493.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.